Carcinoembryonic antigen (CEA) has been used as a tumor biomarker in gastrointestinal cancer for decades, but its effect in predicting the survival rate of patients with CRC is still not perfect (Locker et al., 2006; Primrose et al., 2014). This evidence concerns the gene CEACAM5 and neoplasm.